Search
for
Sort by
Research
840-870 / 1000+ resultsresearch No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
research Adjunctive Approaches for Androgenetic Alopecia: A Clinical Review of Nutritional, Light-Based, Topical, and Lifestyle Interventions
A holistic approach, including diet and stress management, may improve androgenetic alopecia treatment outcomes.
research Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments
Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
research Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern Hair loss in Hair transplant patients using a modified delphi process
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific dosing and timing guidelines.
research Patient Perspectives regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation
Patients found AI helpful for alopecia diagnosis but want it to support, not replace, doctors.
research Hair Loss and Zinc Deficiency: A Cross-Sectional Study
Zinc levels don't significantly affect hair loss, so testing for zinc isn't necessary.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
research Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
Oral minoxidil users, especially for hypertension, may risk heart issues, and better monitoring guidelines are needed for alopecia patients.
research Topical Tacrolimus, Clobetasol, and Minoxidil (TCM) for Primary Cicatricial Alopecias: A Retrospective Analysis of Clinical Outcomes and Safety
TCM is an effective and safe treatment for primary cicatricial alopecias.
research Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
research Successful Treatment of Coexisting Alopecia Areata and Bullous Pemphigoid With Dupilumab: A Case Report
Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
research Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction
Improving education, insurance, and support can help scarring alopecia patients access better care.
research Improvement in Scalp Hair Appearance Following Treatment With a Non‐Ablative Fractional Laser: A Retrospective Observational Study
Non-ablative fractional laser treatment safely improves hair growth and scalp appearance.
research Hair Transplant: Patient Candidacy, Medical Optimization, and Surgical Considerations
Hair transplantation can significantly improve life quality for those with chronic hair loss.
research Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
research Alopecia Treatments in Breastfeeding: Safety and Clinical Considerations
Safe alopecia treatments for breastfeeding women are limited due to potential risks to infants.
research Supratherapeutic Vitamin D with a Hair Nutraceutical: A Case Report
research Alopecia in Female Athletes Using Androgenic and Anabolic Steroids: Pathophysiology and Management
Female athletes using steroids risk hair loss and need better education and treatment.
research Use of low-dose oral minoxidil for hair growth in transgender and gender non-binary adult patients: a retrospective cohort study
research Impact of Age on Response to Platelet-Rich Plasma Therapy
Younger patients may see better results from PRP therapy for hair growth, but age doesn't significantly affect overall outcomes.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Evaluating the accuracy of patient-reported hair outcomes versus trichometric measurements in PRP therapy
Patient-reported hair improvements align with actual hair density changes, not hair width.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Key considerations of injectable minoxidil for alopecia
Injectable minoxidil may be effective for hair loss but is costly and requires more research.
research Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review
Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.
research Treatment of Androgenetic Alopecia with Low Dose Oral Minoxidil Monotherapy Compared to Combination Therapy with Dutasteride or Finasteride
Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.